1. Generics Bulletin
  2. >>Business
  3. >>Deals

Aurobindo Hits Back Over Sandoz Delay Rumors

Media Reports On FTC Discussions Are ‘Factually Inaccurate’

 
• By Dave Wallace

Aurobindo has hit back over rumors that completion of its pending transaction to acquire Sandoz’ US dermatology and oral-solids businesses has been delayed until next year over FTC information requests.

Cubes_Fact
Aurobindo has criticized inaccurate reporting of the Sandoz deal • Source: Shutterstock

Media reports over delays to the completion of Aurobindo’s deal to acquire Sandoz’ US dermatology and oral-solids businesses contain inaccuracies and mischaracterize the current status of the regulatory approval process, according to the Indian company.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By Adam Zamecnik

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By Dean Rudge

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By Dean Rudge

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera

 
• By Dave Wallace

India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.

More from Business

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By Dean Rudge

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Meitheal Adds To US Liraglutide List As It Looks To Ease Shortage Concerns

 
• By Dean Rudge

Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.